← All trials
NCT05347576
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 21, 2022
- Primary completion
- May 2, 2022
- Completion date
- May 9, 2022
- First posted
- Apr 26, 2022
- Last posted
- Jun 30, 2022
- Enrollment
- 31
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Chong Kun Dang PharmaceuticalLead sponsor
- Chonbuk National UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.